Lineage Specific Effects of IL10 In Autoimmunity
Lineage Specific Effects of IL10 In Autoimmunity
批准号:
8707595
负责人:
Terrence L Geiger
金额:
$41.13万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-08 至 2014-07-31
关键词:
AddressAffectAlopeciaAnti-Inflammatory AgentsAnti-inflammatoryAutoimmune DiseasesAutoimmune ProcessAutoimmunityB-LymphocytesBiological ModelsCell LineageCellsCharacteristicsColitisComplexDataDevelopmentDiseaseDisease modelDisease susceptibilityDissectionEngineeringEnvironmentEragrostisExperimental Autoimmune EncephalomyelitisGenetic VariationGoalsImmuneImmune responseImmune systemImmunosuppressive AgentsImmunotherapyIndividualInflammationInflammatoryInterleukin-10KineticsKnowledgeLaboratoriesLongevityMechanicsMediatingMemoryModelingMusNatural ImmunityPathogenicityPathologicPathologyPathway interactionsPharmacotherapyPredispositionProductionProteinsRegulatory T-LymphocyteResolutionRoleSepsisSeveritiesSignal PathwaySignal TransductionSourceSystemT cell responseT-Cell ProliferationT-LymphocyteTherapeuticTranslationsbasecell typecytokinedesigngenetic variantimmune functionimmunopathologyimprovedin vivoinsightmacrophageneutrophilnext generationnovel therapeutic interventionoverexpressionpalliativepathogenprogramsreceptorresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): IL10 is a predominantly anti-inflammatory cytokine that is critical in setting immune response amplitude. Genetic variation in IL10 or IL10R expression or function is associated with susceptibility to autoimmune and inflammatory diseases. The efficacy of many immunomodulatory therapies is IL10 dependent. Nevertheless, pharmacotherapy with IL10 has shown little benefit in several diseases, and in some experimental settings overexpression or pharmacologic treatment with IL10 can even promote autoimmune inflammation. We hypothesized that differences in the lineage specific effects of IL10 may in part explain the variability of its activity in vivo. To dissect IL10's lineage specifi actions, we generated mice conditionally deficient in the IL10-selective chain of the IL10 receptor, IL10R?. In preliminary studies, we analyzed deficiency of IL10R? on T cells, Foxp3+ regulatory T cells, B cells and macrophage in a model autoimmune disease, experimental allergic encephalomyelitis (EAE). Our findings indicated that pro- and anti- inflammatory functions of IL10 segregate in a lineage dependent manner. Further, IL10 has heterogeneous actions within a lineage, and these may have opposing effects on that lineage's pathogenicity. In this proposal we will use EAE as a model system to explore how the lineage specific effects of IL10 influence the development and progression of autoimmunity. We demonstrated that, surprisingly, the T cell response to IL10 worsened EAE. We hypothesize that IL10 helps sustain the effector T cells (Teff) responsible for immunopathology by inhibiting their terminal differentiation and promoting their survival. In Aim 1, we will determine how IL10's actions on T cells promote immunopathology in EAE. We will address mechanisms of IL10-mediated modulation of T cell proliferation, survival, and memory in vivo, how the immune environment influences the production and effects of IL10, how IL10R signal quality, kinetics, and magnitude influence its T-specific activities, and relevant cellular sources for IL10 affecting the T cell response. In contrast to Teff, the IL10 response of Foxp3+ regulatory T cells suppressed EAE. We hypothesize that IL10 acts to support Treg longevity and suppressive capacity during inflammation. In Aim 2 we will analyze IL10's influence on Treg survival, proliferation, maturation, and function during EAE. IL10 acts globally to limit EAE severity, yet its T cell-specific actions promote disease. In Aim 3 we will identify and begin to characterize the cell lineages responsible for IL10's palliative effects in EAE. Dissecting how IL10 variably influences different cell lineages during autoimmunity will provide us with an improved mechanistic understanding of IL10's regulatory actions, and insights that will aid in the rational design of ne therapeutics that modulate inflammation through the IL10 pathway.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.4049/jimmunol.1800016
发表时间:
2018-11-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Li B, Jones LL, Geiger TL]
通讯作者:
Geiger TL
TREATMENT OF AUTOIMMUNITY WITH RECEPTOR-MODIFIED T CELLS
-
批准号:7058213
-
项目类别:
-
资助金额:$36.62万
-
财政年份:2004
-
负责人:Terrence L Geiger
-
依托单位:
TREATMENT OF AUTOIMMUNITY WITH RECEPTOR-MODIFIED T CELLS
-
批准号:6877143
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2004
-
负责人:Terrence L Geiger
-
依托单位:
TREATMENT OF AUTOIMMUNITY WITH RECEPTOR-MODIFIED T CELLS
-
批准号:6780272
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2004
-
负责人:Terrence L Geiger
-
依托单位:
TREATMENT OF AUTOIMMUNITY WITH RECEPTOR-MODIFIED T CELLS
-
批准号:7387338
-
项目类别:
-
资助金额:$34.88万
-
财政年份:2004
-
负责人:Terrence L Geiger
-
依托单位:
TREATMENT OF AUTOIMMUNITY WITH REGULATORY T LYMPHOCYTES
-
批准号:7649567
-
项目类别:
-
资助金额:$42.0万
-
财政年份:2004
-
负责人:Terrence L Geiger
-
依托单位:
TREATMENT OF AUTOIMMUNITY WITH REGULATORY T LYMPHOCYTES
-
批准号:8441537
-
项目类别:
-
资助金额:$38.69万
-
财政年份:2004
-
负责人:Terrence L Geiger
-
依托单位:
TREATMENT OF AUTOIMMUNITY WITH RECEPTOR-MODIFIED T CELLS
-
批准号:7217456
-
项目类别:
-
资助金额:$35.56万
-
财政年份:2004
-
负责人:Terrence L Geiger
-
依托单位:
TREATMENT OF AUTOIMMUNITY WITH REGULATORY T LYMPHOCYTES
-
批准号:7778382
-
项目类别:
-
资助金额:$41.58万
-
财政年份:2004
-
负责人:Terrence L Geiger
-
依托单位:
TREATMENT OF AUTOIMMUNITY WITH REGULATORY T LYMPHOCYTES
-
批准号:8241096
-
项目类别:
-
资助金额:$41.16万
-
财政年份:2004
-
负责人:Terrence L Geiger
-
依托单位:
TREATMENT OF AUTOIMMUNITY WITH REGULATORY T LYMPHOCYTES
-
批准号:8046458
-
项目类别:
-
资助金额:$41.16万
-
财政年份:2004
-
负责人:Terrence L Geiger
-
依托单位:
Inducing Immune Tolerance with Receptor Modified T Cells
-
批准号:6534342
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2001
-
负责人:Terrence L Geiger
-
依托单位:
Inducing Immune Tolerance with Receptor Modified T Cells
-
批准号:6352708
-
项目类别:
-
资助金额:$22.38万
-
财政年份:2001
-
负责人:Terrence L Geiger
-
依托单位:
Inducing Immune Tolerance with Receptor Modified T Cells
-
批准号:6646466
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2001
-
负责人:Terrence L Geiger
-
依托单位:
TREATMENT OF EAE USING GENETICALLY MODIFIED CTL
-
批准号:6168955
-
项目类别:
-
资助金额:$11.83万
-
财政年份:1997
-
负责人:Terrence L Geiger
-
依托单位:
TREATMENT OF EAE USING GENETICALLY MODIFIED CTL
-
批准号:2886073
-
项目类别:
-
资助金额:$0.7万
-
财政年份:1997
-
负责人:Terrence L Geiger
-
依托单位:
TREATMENT OF EAE USING GENETICALLY MODIFIED CTL
-
批准号:2671471
-
项目类别:
-
资助金额:$8.72万
-
财政年份:1997
-
负责人:Terrence L Geiger
-
依托单位:
TREATMENT OF EAE USING GENETICALLY MODIFIED CTL
-
批准号:6372586
-
项目类别:
-
资助金额:$11.83万
-
财政年份:1997
-
负责人:Terrence L Geiger
-
依托单位:
TREATMENT OF EAE USING GENETICALLY MODIFIED CTL
-
批准号:6096336
-
项目类别:
-
资助金额:$9.1万
-
财政年份:1997
-
负责人:Terrence L Geiger
-
依托单位:
TREATMENT OF EAE USING GENETICALLY MODIFIED CTL
-
批准号:2386044
-
项目类别:
-
资助金额:$8.61万
-
财政年份:1997
-
负责人:Terrence L Geiger
-
依托单位:
海外基金